Related Experiment Video
Updated: Sep 18, 2025
08:01
Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines
Published on: April 21, 2022
2.0K
A novel mesothelioma molecular classification based on malignant cell differentiation
Jun Liu1, Yifan Liu2, Yuwei Lu3
1Department of Anesthesiology, Shanghai Pulmonary Hospital Affiliated to Tongji University School of Medicine, Shanghai, 200000, China.
Cancer Cell International
|June 24, 2025
Summary
This study introduces a new molecular classification for mesothelioma (MESO) based on tumor cell differentiation, identifying three subtypes with distinct prognoses. A predictive model using key genes may improve patient management.
Area of Science:
- Oncology
- Genomics
- Bioinformatics
Background:
- Mesothelioma (MESO) exhibits high tumor cell heterogeneity and poor differentiation, driving aggressive behavior.
- A molecular classification system for MESO based on tumor cell differentiation states is currently lacking.
Purpose of the Study:
- To develop a novel molecular classification for mesothelioma based on tumor cell differentiation.
- To identify key genes and construct regulatory networks for MESO subtypes.
- To develop a prognostic prediction model for MESO patients.
Main Methods:
- Single-cell RNA sequencing data from the GEO database was analyzed using dimensionality reduction and clustering.
- Multi-omics analysis and regulatory network construction were performed.
- A prognostic prediction model was developed using key tumor cell differential genes (TCDGs).
Main Results:
- Eight malignant cell subtypes in MESO were identified.
- MESO was classified into three subtypes (Malignant, Benign, and Neutral differentiation-related) with prognostic differences.
- A validated prediction model using 12 TCDGs was developed, and 14 potential inhibitors were identified. Clinical specimens confirmed subtyping reliability.
Conclusions:
- A novel molecular classification system for mesothelioma has been established.
- A prognostic prediction model based on TCDGs offers potential benefits for MESO patient management.
